Tema ETF's GLP-1, Obesity & Cardiometabolic ETF (HRTS) increased 26% due to weight loss stock demand.

Tema ETFs' GLP-1, Obesity & Cardiometabolic ETF (HRTS), launched in November, has increased 26% due to weight loss stock demand. CEO Maurits Pot believes the ETF's focus on GLP-1 treatments' potential for wider use will lower drug prices, making them more accessible within 2-3 years. Top holdings include Eli Lilly (Mounjaro) and Novo Nordisk (Ozempic/Wegovy).

Articles

NBC Connecticut

NBC Philadelphia

NBC Chicago

NBC DFW

-- show less --

Further Reading

Related Stories